Walgreen, Kroger, Safeway, SuperValu, and HEB have sued Pfizer and Ranbaxy, accusing the drug manufacturers of conspiring to delay generic versions of Lipitor (atorvastatin). Pfizer markets Lipitor and Ranbaxy manufactures the generic version.
The conspiracy allegedy called for a fraudulent patent, sham litigation, a pay-for-delay agreement, and agreements with pharmacy benefit managers requiring them to buy more Lipitor. The retailers claim that these actions kept Lipitor off the market 20 months past the expiration of the original patent.
Lipitor is used to lower cholesterol. It is the best-selling drug in pharmaceutical history.
Full content: Reuters
Related content: Federal Trade Commission Suffers Another Setback in Its Campaign to End Pharmaceutical Reverse-Settlement Agreements
Want more news? Subscribe to CPI’s free daily newsletter for more headlines and updates on antitrust developments around the world.
Featured News
Trump Fires Head of Copyright Office, Throwing U.S. AI Policy Into Disarray
May 12, 2025 by
CPI
Delta, Korean Air Buy Into WestJet in Major Cross-Border Deal
May 12, 2025 by
CPI
Trump Targets Big Pharma With Tough New Drug Pricing Rules
May 12, 2025 by
CPI
Geradin Partners Expands London Team with New Partner Hire
May 12, 2025 by
CPI
H-E-B Joins Antitrust Battle Against Teva Over MS Drug Monopoly
May 12, 2025 by
CPI
Antitrust Mix by CPI
Antitrust Chronicle® – Mergers in Digital Markets
Apr 21, 2025 by
CPI
Catching a Killer? Six “Genetic Markers” to Assess Nascent Competitor Acquisitions
Apr 21, 2025 by
John Taladay & Christine Ryu-Naya
Digital Decoded: Is There More Scope for Digital Mergers In 2025?
Apr 21, 2025 by
Colin Raftery, Michele Davis, Sarah Jensen & Martin Dickson
AI In the Mix – An Ever-Evolving Approach to Jurisdiction Over Digital Mergers in Europe
Apr 21, 2025 by
Ingrid Vandenborre & Ketevan Zukakishvili
Antitrust Enforcement Errors Due to a Failure to Understand Organizational Capabilities and Dynamic Competition
Apr 21, 2025 by
Magdalena Kuyterink & David J. Teece